<DOC>
	<DOC>NCT00593593</DOC>
	<brief_summary>This study has 4 phases: screening phase (visit 1), treatment phase (visit 2 - 6 mths after treatment initiation), and end of treatment phase (visit 3 - end of year 1). Only in the case a serious adverse event (SAE) arises, will there be a follow up phase (visit 4).</brief_summary>
	<brief_title>Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Subject should fulfil criteria for the subscription of AVODART as these are mentioned in the SPC Subject should be diagnosed with benign prostate hyperplasia Subject's prostate volume should be equal or greater than 30 cm3 Known hypersensitivity to any of the AVODART compounds Suffers from a serious illness which either is not properly controlled or as per investigator´s judgment could interfere with the subject´s compliance into the trial Receives treatment with enzyme inhibitors CYP3A4 and CYP3A5. History of severe liver failure</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>benign prostate hyperplasia</keyword>
	<keyword>Dutasteride</keyword>
	<keyword>pharmacovigilance</keyword>
</DOC>